Drug Trial Radar · NCT00729937
Strategies Using Off-Patent Antibiotics for Methicillin Resistant S. Aureus "STOP MRSA"
Last checked: Nov 19, 2026Latest source record: Feb 18, 2015 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
2,265
Actual
Start
Apr 2009
Primary completion
May 2013
Study completion Jun 2013
Sponsor
- Sponsor type
- NIH
- First posted
- Aug 8, 2008
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 13 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine the optimal outpatient treatment strategy of uncomplicated skin and soft tissue infection (SSTI) in areas of the United States where the prevalence of Community-Acquired Methicillin-Resistant Staphylococcus (S.) aureus (CA-MRSA) is high. Infection with the S. aureus bacteria that is resistant to antibiotics is a cause of SSTIs. Three oral antibiotics will be tested for off patent treatment. Patients will receive Trimethoprim/Sulfamethoxazole (TMP/SMX), placebo (substance containing no medication), clindamycin, or cephalexin or some combination of these. The study population will include 2,235 volunteers, children 13 years of age and over and adults presenting to 5 large urban Emergency Departments. Therapy for acute uncomplicated SSTIs, including abscess, infected wound, and cellulitis will start on the day of enrollment. Participants may be involved in study related procedures for about 9 weeks.
Conditions
- Staphylococcal Infection
Interventions
CephalexinDrug
500 mg, four times per day.
ClindamycinDrug
300 mg, four times per day.
PlaceboOther
Placebo tablet administered orally.
Trimethoprim-sulfamethoxazoleDrug
4 single strength Trimethoprim/Sulfamethoxazole (TMP/SMX), 80 mg/400 mg each, twice per day.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Clinical Cure as of the Test-of-Cure (TOC) Visit in the Per Protocol PopulationTime frame: Days 14-21
Locations
5 sites in 1 country. Site status is shown where the registry gives one.
Maricopa Medical Center - Emergency Medicine
Phoenix, Arizona
University of California Los Angeles - Olive View Medical Center
Sylmar, California
Johns Hopkins University at Mount Washington - Emergency Medicine
Baltimore, Maryland
Truman Medical Center - Hospital Hill
Kansas City, Missouri
Temple University Hospital
Philadelphia, Pennsylvania
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.